Bevacizumab exerts anti-tumor effects by binding to VEGF-A, preventing VEGF-A from interacting with VEGFR-1 and VEGFR-2, blocking the signaling pathway of angiogenesis, and inhibiting the formation of tumor neovasculature, thus inhibiting the growth of tumor cells (Gerber and Ferrara, 2005) (Figure 7). Here, KDR is linked to neoplasm.